Leadership

Original innovation in drug development is vital for Chinese pharmas to grow into international majors within a decade, while originality is not necessarily restricted to the first-in-class category, Xingli Wang, head of Fosun Pharma’s Global R&D, shares his thoughts with Scrip.

Setting out plans to support career development and create learning and networking opportunities for women in the UK generics and biosimilars industry, local off-patent association the BGMA has named Accord’s Clara Carter as chair of a new women’s networking group.

23andMe cut 40% of its workforce and will discontinue its therapeutic program as part of ongoing restructuring. This comes after a data breach, series of layoffs and the resignation of its board members.

Yuhan eyes successors to lazertinib after US approval, leadership dispute at Hanmi drags on and SK Bioscience completes CDMO acquisition.

France’s medtech sector is strong, growing and innovative. Medtech Insight spoke to several French medtech leaders about the unique features and pitfalls their industry may face.

Darrin Schellin leads Pharma Tech; PLT expands leadership with Weiss as brand mmanagement head; Tuttle joins ProPharma as CFO; Burgher leads Arbonne marketing, growth; Evvy appoints first medical chief; Vitaquest appoints David Alcaraz quality assurance head; and Lemon Water leadership in transition from founder.

23andMe cut 40% of its workforce and will discontinue its therapeutic program as part of ongoing restructuring. This comes after a data breach, series of layoffs and the resignation of its board members.

Xytogen Biotech’s Factorfive stem cell-based skin care delivers benefits that are greater than the company claims, says founder and CEO John Aylworth. Available mostly through clinicians’ offices, the formulas are based on a proprietary process that triggers stem cells to send out growth factor signals, which are captured in a ‘conditioned media’ and used as the basis for products.

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Medtech Insight talked with GE HealthCare’s chief AI officer Parminder “Parry” Bhatia at HLTH about the firm’s new CareIntellect for Oncology offering to help clinicians make efficient use of multimodal patient data, his vision for projects within AI Innovation Lab, and the future of AI in health care.